China approves human testing for a potential coronavirus vaccine

On August 22, China approved human testing of an experimental COVID-19 vaccine manufactured from cultivated insect cells, local government in southwestern city of Chengdu said in a statement. insect-based vaccine was developed by West China Hospital of Sichuan University in Chengdu and was approved by National Medical Products ministration to enter into human clinical trial st. China has eight or vaccines in different sts of clinical trials according to reports. Insect cells used in potential vaccine to manufacture protein could enhance large-scale production, city government of Chengdu said in a tice, as per reports.

vaccine was tested on monkeys, and h promising results to compromise SARS-CoV-2 strain in patient’s body without side-effects, tice ded. As per health experts, vaccine uses insect cells to multiply in culture medium and introduces gene of COVID-19 into insect cells. refore, post infusion, cell would transform into an entity that speeds production of high-quality recombinant vaccine proteins, according to reports. insect cell in vaccine also purifies protein for refinement. Earlier, development and marketing of cervical cancer and influenza insect-based vaccines in Europe and US has demonstrated its successful results and thus backs safety of COVID-19 insect-based vaccine. 

Re: ICMR Developing Portal For Info On COVID-19 Vaccine In India & Abro

Re: Moderna's COVID-19 Vaccine: 13,194 People Enroll For Phase 3 Trials

China's Bio Farma to begin phase III trials

Earlier, China’s Sivac collaborated with Indonesia's state-owned pharmaceutical company Bio Farma to begin phase III, final clinical trials for Chinese experimental COVID-19 vaccine CoronaVac next month. PT Bio Farma (Persero) COVID-19 vaccine trials will involve 1,620 participants. Chinese pharmaceutical firm Sivac Biotech Ltd anunced manufacture of at least 2,400 doss of vaccines if trials are successful, according to reports.  Bio Farma Research & Development Project Integration Manr Dr. Neni Nurainy was quoted as saying that vaccines will be internally tested at Bio Farma's lab, but clinical trial will be carried out by Pjjaran University. Furr, State-Owned Enterprises (SOEs) Minister Erick Thohir, said that pharmaceutical holding company Bio Frama is expected to produce 250 million doses of  Sivac coronavirus vaccine per year by end of 2020.  

Re: Trump Accuses FDA 'Deep State' Of Slowing Vaccine Development To Sabot His Re-election

Re: Sipharm's COVID-19 Vaccine Approved By Peru, Morocco For Phase III Trials

(Im Credit: PTI)